Chitosan glycerophosphate-based semirigid dexamethasone eluting biodegradable stent

Benjamin S. Bleier, David P. Paulson, Bert W. O'Malley, Daqing Li, James N. Palmer, Alexander G Chiu, Noam A. Cohen

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Chitosan is a polysaccharide derived from chitin deacetylation, which can form a biodegradable matrix capable of reversibly binding dexamethasone. The purpose of this study was to optimize the chitosan formulation to produce a pliable sheet, to assess the innate longevity and inflammatory potential of the polymer, and to study the in vivo rate of dexamethasone release over time. Methods: Chitosan glycerophosphate (CGP) sheets were produced with varying degrees of deacetylation (70-100%) and analyzed for structural integrity. Two-squared centimeter sheets of 91.7% deacetylated CGP were mixed with dexamethasone and implanted in 12 rabbit maxillary sinuses. Nasal lavage and peripheral blood samples were tested for dexamethasone levels by enzyme-linked immunosorbent assay (ELISA) over 15 days. Sinuses were examined histologically on postoperative days 3, 7, and 15 for persistence of the stent and degree of inflammation when compared with CGP alone. Results: The 91.7% deacetylated CGP formulation was found to have optimal mechanical properties and remained present with moderate degradation and negligible inflammation through postoperative day 15. Dexamethasone levels were detectable in nasal lavage and blood samples through postoperative day 15 and decayed over time (lavage: day 0, 7.70 ± 0.97 ng/mL, and day 15, 2.53 ± 1.71 ng/mL; blood: day 3, 2.51 ± 0.14 ng/mL, and day 15, 1.70 ± 0.36 ng/mL). Conclusion: CGP may be used to create a semirigid sheet that is malleable, inert, and capable of eluting steroid over 15 days when implanted intranasally. This material may be used to create a pharmacologically active stent that spontaneously degrades over time.

Original languageEnglish (US)
Pages (from-to)76-79
Number of pages4
JournalAmerican Journal of Rhinology and Allergy
Volume23
Issue number1
DOIs
StatePublished - Jan 2009
Externally publishedYes

Fingerprint

Glycerophosphates
Chitosan
Dexamethasone
Stents
Nasal Lavage
Inflammation
Chitin
Maxillary Sinus
Therapeutic Irrigation
Polysaccharides
Polymers
Enzyme-Linked Immunosorbent Assay
Steroids
Rabbits

Keywords

  • Chitosan
  • Drug
  • Eluting
  • Glycerophosphate
  • Rabbit
  • Rabbit model
  • Sinusitis
  • Stent
  • Steroids

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Immunology and Allergy

Cite this

Chitosan glycerophosphate-based semirigid dexamethasone eluting biodegradable stent. / Bleier, Benjamin S.; Paulson, David P.; O'Malley, Bert W.; Li, Daqing; Palmer, James N.; Chiu, Alexander G; Cohen, Noam A.

In: American Journal of Rhinology and Allergy, Vol. 23, No. 1, 01.2009, p. 76-79.

Research output: Contribution to journalArticle

Bleier, Benjamin S. ; Paulson, David P. ; O'Malley, Bert W. ; Li, Daqing ; Palmer, James N. ; Chiu, Alexander G ; Cohen, Noam A. / Chitosan glycerophosphate-based semirigid dexamethasone eluting biodegradable stent. In: American Journal of Rhinology and Allergy. 2009 ; Vol. 23, No. 1. pp. 76-79.
@article{51b7d9283e36433abff720f733ed1937,
title = "Chitosan glycerophosphate-based semirigid dexamethasone eluting biodegradable stent",
abstract = "Background: Chitosan is a polysaccharide derived from chitin deacetylation, which can form a biodegradable matrix capable of reversibly binding dexamethasone. The purpose of this study was to optimize the chitosan formulation to produce a pliable sheet, to assess the innate longevity and inflammatory potential of the polymer, and to study the in vivo rate of dexamethasone release over time. Methods: Chitosan glycerophosphate (CGP) sheets were produced with varying degrees of deacetylation (70-100{\%}) and analyzed for structural integrity. Two-squared centimeter sheets of 91.7{\%} deacetylated CGP were mixed with dexamethasone and implanted in 12 rabbit maxillary sinuses. Nasal lavage and peripheral blood samples were tested for dexamethasone levels by enzyme-linked immunosorbent assay (ELISA) over 15 days. Sinuses were examined histologically on postoperative days 3, 7, and 15 for persistence of the stent and degree of inflammation when compared with CGP alone. Results: The 91.7{\%} deacetylated CGP formulation was found to have optimal mechanical properties and remained present with moderate degradation and negligible inflammation through postoperative day 15. Dexamethasone levels were detectable in nasal lavage and blood samples through postoperative day 15 and decayed over time (lavage: day 0, 7.70 ± 0.97 ng/mL, and day 15, 2.53 ± 1.71 ng/mL; blood: day 3, 2.51 ± 0.14 ng/mL, and day 15, 1.70 ± 0.36 ng/mL). Conclusion: CGP may be used to create a semirigid sheet that is malleable, inert, and capable of eluting steroid over 15 days when implanted intranasally. This material may be used to create a pharmacologically active stent that spontaneously degrades over time.",
keywords = "Chitosan, Drug, Eluting, Glycerophosphate, Rabbit, Rabbit model, Sinusitis, Stent, Steroids",
author = "Bleier, {Benjamin S.} and Paulson, {David P.} and O'Malley, {Bert W.} and Daqing Li and Palmer, {James N.} and Chiu, {Alexander G} and Cohen, {Noam A.}",
year = "2009",
month = "1",
doi = "10.2500/ajra.2009.23.3268",
language = "English (US)",
volume = "23",
pages = "76--79",
journal = "American Journal of Rhinology and Allergy",
issn = "1945-8924",
publisher = "OceanSide Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Chitosan glycerophosphate-based semirigid dexamethasone eluting biodegradable stent

AU - Bleier, Benjamin S.

AU - Paulson, David P.

AU - O'Malley, Bert W.

AU - Li, Daqing

AU - Palmer, James N.

AU - Chiu, Alexander G

AU - Cohen, Noam A.

PY - 2009/1

Y1 - 2009/1

N2 - Background: Chitosan is a polysaccharide derived from chitin deacetylation, which can form a biodegradable matrix capable of reversibly binding dexamethasone. The purpose of this study was to optimize the chitosan formulation to produce a pliable sheet, to assess the innate longevity and inflammatory potential of the polymer, and to study the in vivo rate of dexamethasone release over time. Methods: Chitosan glycerophosphate (CGP) sheets were produced with varying degrees of deacetylation (70-100%) and analyzed for structural integrity. Two-squared centimeter sheets of 91.7% deacetylated CGP were mixed with dexamethasone and implanted in 12 rabbit maxillary sinuses. Nasal lavage and peripheral blood samples were tested for dexamethasone levels by enzyme-linked immunosorbent assay (ELISA) over 15 days. Sinuses were examined histologically on postoperative days 3, 7, and 15 for persistence of the stent and degree of inflammation when compared with CGP alone. Results: The 91.7% deacetylated CGP formulation was found to have optimal mechanical properties and remained present with moderate degradation and negligible inflammation through postoperative day 15. Dexamethasone levels were detectable in nasal lavage and blood samples through postoperative day 15 and decayed over time (lavage: day 0, 7.70 ± 0.97 ng/mL, and day 15, 2.53 ± 1.71 ng/mL; blood: day 3, 2.51 ± 0.14 ng/mL, and day 15, 1.70 ± 0.36 ng/mL). Conclusion: CGP may be used to create a semirigid sheet that is malleable, inert, and capable of eluting steroid over 15 days when implanted intranasally. This material may be used to create a pharmacologically active stent that spontaneously degrades over time.

AB - Background: Chitosan is a polysaccharide derived from chitin deacetylation, which can form a biodegradable matrix capable of reversibly binding dexamethasone. The purpose of this study was to optimize the chitosan formulation to produce a pliable sheet, to assess the innate longevity and inflammatory potential of the polymer, and to study the in vivo rate of dexamethasone release over time. Methods: Chitosan glycerophosphate (CGP) sheets were produced with varying degrees of deacetylation (70-100%) and analyzed for structural integrity. Two-squared centimeter sheets of 91.7% deacetylated CGP were mixed with dexamethasone and implanted in 12 rabbit maxillary sinuses. Nasal lavage and peripheral blood samples were tested for dexamethasone levels by enzyme-linked immunosorbent assay (ELISA) over 15 days. Sinuses were examined histologically on postoperative days 3, 7, and 15 for persistence of the stent and degree of inflammation when compared with CGP alone. Results: The 91.7% deacetylated CGP formulation was found to have optimal mechanical properties and remained present with moderate degradation and negligible inflammation through postoperative day 15. Dexamethasone levels were detectable in nasal lavage and blood samples through postoperative day 15 and decayed over time (lavage: day 0, 7.70 ± 0.97 ng/mL, and day 15, 2.53 ± 1.71 ng/mL; blood: day 3, 2.51 ± 0.14 ng/mL, and day 15, 1.70 ± 0.36 ng/mL). Conclusion: CGP may be used to create a semirigid sheet that is malleable, inert, and capable of eluting steroid over 15 days when implanted intranasally. This material may be used to create a pharmacologically active stent that spontaneously degrades over time.

KW - Chitosan

KW - Drug

KW - Eluting

KW - Glycerophosphate

KW - Rabbit

KW - Rabbit model

KW - Sinusitis

KW - Stent

KW - Steroids

UR - http://www.scopus.com/inward/record.url?scp=70149102853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70149102853&partnerID=8YFLogxK

U2 - 10.2500/ajra.2009.23.3268

DO - 10.2500/ajra.2009.23.3268

M3 - Article

VL - 23

SP - 76

EP - 79

JO - American Journal of Rhinology and Allergy

JF - American Journal of Rhinology and Allergy

SN - 1945-8924

IS - 1

ER -